GlycoMimetics

GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

GlycoMimetics reports strong Q4 performance and optimistic clinical advancements

GlycoMimetics delivered a robust performance in Q4 2022, driven by positive clinical outcomes and strategic financial decisions. The company's focus on uproleselan and promising interim utility analysis sets a solid foundation for future growth. While challenges like managing expenses and meeting trial milestones exist, GlycoMimetics is well-positioned to capitalize on opportunities in the biopharmaceutical sector.

GlycoMimetics excels in AML trials, secures funding for future growth

GlycoMimetics showcased strong performance in both clinical trials and financial standing, positioning the company well for future growth.
While challenges in managing expenses and navigating industry complexities exist, opportunities for expansion and innovation through partnerships are promising.

GlycoMimetics advances clinical trials and secures funding until late 2024

GlycoMimetics showcased strong progress in their clinical trials and financial stability during the Q2 2023 Earnings Call. With FDA clearance for Phase III uproleselan study and a cash runway until late 2024, the company is well-positioned for future growth. Challenges include successful trial execution and maintaining financial discipline.

GlycoMimetics progresses in AML trials, eyes positive Phase III results

GlycoMimetics demonstrated strong performance in advancing its clinical pipeline, with a focus on uproleselan in AML.
While facing challenges like delays in studies and increased expenses, the company remains optimistic about future prospects.
Opportunities lie in presenting data at conferences, exploring market expansion, and anticipating positive Phase III results by Q2 2024.

GlycoMimetics reports progress in trials and financial strength for growth

GlycoMimetics' Q4 2023 earnings call showcased positive clinical trial outcomes, strong financial standing, and a strategic focus on addressing unmet medical needs. The company's upcoming milestones, including the Phase III trial results and NDA submission, indicate promising growth potential.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GlycoMimetics' (GLYC) CEO Rachel King on Q3 2020 Results - Earnings Call Transcript

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the third quarter ended September 30, 2020, and highlighted recent company events. Cash and cash equivalents at September 30, 2020 were $142.9 million. “During the third quarter, both late-stage trials of uproleselan – the Company-sponsored Phase 3 trial in relapsed/refractory AML patients as well as the NCI's study in newly-diagnosed AML patients fit for chemotherapy – progressed in the

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2020

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that three abstracts including data from the Company's clinical and research portfolio have been accepted for oral presentations and two abstracts have been accepted for poster presentations at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held virtually December 5-8, 2020. Of particular note are primary and key secondary endpoint data from additional analysis of the Phase 3

GlycoMimetics Program Data to be Highlighted Via Three Oral Presentations and Two Posters at 62nd American Society of Hematology Annual Meeting and Exposition

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its third quarter financial results on Friday, November 6, 2020, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants or (216) 562-0466 for international participants, with participant code 3073766. Participants are encouraged to connect 15 minutes in advance of the call to ensure that all callers are abl

GlycoMimetics to Report Third Quarter Financial Results on November 6, 2020

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that new post hoc analyses of the Phase 3 RESET study evaluating the efficacy of rivipansel, its wholly-owned product candidate, in VOC show that pediatric patients treated with rivipansel within approximately 30 hours of the onset of acute crisis pain experienced statistically significant improvements in the primary efficacy endpoint of time to readiness for discharge (TTRFD) compared to placebo as well as in t

New Pediatric and Secondary Endpoint Data from Rivipansel Phase 3 RESET Trial Presented at The Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) Meeting

GlycoMimetics is undervalued based on its AML therapy potential.

GlycoMimetics' Possible Rivipansel Revival

GlycoMimetics' (GLYC) rivipansel gets a Rare Pediatric Disease designation by the FDA for the treatment of SCD in patients 18 years old and younger.

GlycoMimetics' Rivipansel Gets Rare Pediatric Disease Status

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company a Rare Pediatric Disease designation for rivipansel for the treatment of sickle cell disease in patients 18 years old and younger. This designation recognizes the significant needs in pediatric patients. “The FDA’s designation recognizes the morbidity and mortality burdens of sickle cell disease as well as its significant impact during chil

FDA Grants GlycoMimetics Rare Pediatric Disease Designation for Rivipansel for Treatment of Sickle Cell Disease

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc.

GlycoMimetics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

New Preclinical GlycoMimetics Data Suggests Uproleselan With Venetoclax/HMA in AML May Prolong Survival

GlycoMimetics, Inc. (GLYC) CEO Rachel King on Q2 2020 Results - Earnings Call Transcript

GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2020

GlycoMimetics to Report Second Quarter Financial Results on July 31, 2020

GlycoMimetics (GLYC) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

GlycoMimetics (GLYC) in Focus: Stock Moves 8.1% Higher

GlycoMimetics (GLYC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How GlycoMimetics (GLYC) Stock Stands Out in a Strong Industry

GlycoMimetics, Inc. (GLYC) CEO Rachel King on Q1 2020 Results - Earnings Call Transcript

GlycoMimetics' Focus Is On AML Therapy

GlycoMimetics' (GLYC) CEO Rachel King on Q3 2019 Results - Earnings Call Transcript

Journey Medical Corp

Ironwood Pharma

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

Rigel Pharmaceuticals

SPDR S&P Pharmaceuticals ETF

Pharma sector wins in October, making these ETFs and stocks winners.

Pharma Sector Tops in October: Best ETFs & Stocks

Biotech concern GlycoMimetics fell sharply in early August when its out-licensed candidate rivipansel flunked a Phase 3 trial.

GlycoMimetics: Grinding Its Way Back

Much of GlycoMimetics' value was supposed to be in the uproleselan AML therapy.

GlycoMimetics: Still Potential In AML Therapy

NuCana

Falling Knives are companies whose share prices have fallen more than 59% over the past year, generating the interest of investors as they can make huge gains if they bounce back.

Analysts Recommend These 2 Falling Knives (Aug 18)

Investors need to pay close attention to GlycoMimetics (GLYC) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in GlycoMimetics (GLYC) Stock?

GlycoMimetics Inc. (NASDAQ: GLYC) shares were crushed on Monday after the firm announced late-stage results from its sickle cell disease (SCD) trial in conjunction with Pfizer Inc.

Is GlycoMimetics’ Sickle Cell Study Done For?

Shares of GlycoMimetics Inc. GLYC, -1.30% fell 53% in premarket trade Monday after the company announced Friday evening that a Phase 3 trial of a sickle-cell disease drug, developed in partnership with Pfizer Inc.

News for GlycoMimetics Stock (GLYC)